PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Detail   |   Print    Next page > 
     
Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
2026-06-22T    Health Care/Hospital   Medical/Pharmaceuticals 
Sisram Medical Bolsters EBD and Injectables in Thailand to Unlock APAC Growth
2026-06-22T    Cosmetics & Personal Care   Health Care/Hospital   Household/Consumer/Cosmetics   Medical/Pharmaceuticals 
Sisram Medical Bolsters EBD and Injectables in Thailand to Unlock APAC Growth
2026-06-22T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
2026-06-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
2026-06-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing
2026-06-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
2026-06-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall
2026-06-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
2026-06-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
2026-06-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

 

88iv | Home |  Login
Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer
Copyright (C) 2026
Suntek Computer Systems Limited.
All rights reserved